Beyond Parkinson's Disease:
Understanding the Differential
Diagnosis of Parkinsonism

1. The Diagnostic Framework: Parkinsonism vs. Parkinson's Disease

Parkinson's disease accounts for approximately 75–80% of all parkinsonism encountered in general neurological practice. The remainder — secondary and atypical parkinsonisms — are frequently misidentified, with diagnostic delays ranging from months to years before accurate classification. The consequence of misdiagnosis is clinically significant in each direction: over-treatment in reversible forms, and under-preparation in progressive ones.

The cardinal differentiating tool in the initial workup remains the levodopa challenge: a robust, sustained motor response to adequate levodopa doses strongly favors idiopathic Parkinson's disease. Absent or minimal response should prompt systematic evaluation of the categories outlined below. Dopamine transporter (DAT) imaging provides an additional binary distinction — DAT uptake is reduced in neurodegenerative parkinsonisms but preserved in drug-induced and psychogenic forms.

2. The Four Major Non-PD Categories

3. Drug-Induced Parkinsonism (DIP)

Drug-induced parkinsonism is the most prevalent secondary cause, accounting for up to 20% of parkinsonism presentations in some clinical series — and uniquely, the most potentially reversible. The pathophysiology centers on striatal dopamine D2 receptor blockade by dopamine antagonist medications, producing a functional dopaminergic deficit without any underlying nigrostriatal neurodegeneration.

Principal offending drug classes include: typical and atypical antipsychotics; prokinetic and antiemetic dopamine antagonists (metoclopramide, levosulpiride); calcium channel blockers with dopamine antagonist properties (cinnarizine, flunarizine); and certain antivertigo formulations. In elderly patients receiving polypharmacy, the risk is substantially elevated over single-agent exposure.

Clinical features that raise suspicion for DIP over idiopathic Parkinson's disease include: symmetric onset (PD characteristically begins asymmetrically); clear temporal correlation with drug initiation; and preserved olfactory function (anosmia is a hallmark of PD, not DIP). Crucially, DAT SPECT imaging is normal in DIP — a finding that definitively distinguishes it from PD, in which DAT uptake is reduced.

Management centers on withdrawal or substitution of the causative agent. Recovery typically occurs over weeks to months. In a subset of patients — particularly older individuals — parkinsonism persists beyond the expected washout period, raising the possibility of co-existing subclinical PD that was "unmasked" by the offending drug rather than caused by it.

4. Vascular Parkinsonism

Vascular parkinsonism arises from cerebrovascular disease affecting the basal ganglia, thalamus, or the white matter tracts of the nigrostriatal-thalamocortical circuit. It accounts for approximately 3–6% of parkinsonism cases and is strongly associated with chronic vascular risk factor burden: hypertension, diabetes mellitus, hyperlipidemia, and prior cerebrovascular events.

The clinical phenotype is characteristically distinct from idiopathic PD. The predominant manifestation is lower-body parkinsonism — gait disturbance with the characteristic "magnetic gait" (feet appearing glued to the floor), postural instability, and freezing of gait — with relative sparing of upper limb function and resting tremor. This lower-limb predilection reflects the watershed distribution of small vessel ischemic disease in the deep white matter and basal ganglia, where long motor tracts are particularly vulnerable.

Neuroimaging is diagnostically essential: MRI demonstrates periventricular and subcortical white matter hyperintensities, lacunar infarcts, or discrete basal ganglia lesions on T2/FLAIR sequences. Levodopa response is characteristically poor, particularly for the gait disorder, though upper limb rigidity may show partial, inconsistent improvement. Management focuses on aggressive vascular risk factor control to slow progression.

5. Normal Pressure Hydrocephalus (NPH)

Normal pressure hydrocephalus represents a surgically treatable cause of parkinsonism — and one of the most consequential misdiagnoses to miss. The pathophysiology involves impaired CSF reabsorption at the arachnoid granulations, leading to progressive ventriculomegaly and periventricular white matter compression, despite lumbar puncture opening pressures that fall within normal range (hence "normal pressure").

The classical clinical triad — gait apraxia, urinary incontinence, and cognitive impairment, colloquially described as "wet, wobbly, and wacky" — is present in its complete form in fewer than 50% of cases, making partial presentations an ongoing diagnostic challenge. The gait disturbance of NPH has a characteristic appearance: wide-based, short-stepped, with markedly reduced foot clearance and en bloc turning — features that overlap substantially with both Parkinson's disease and vascular parkinsonism.

MRI demonstrates ventriculomegaly disproportionate to cortical atrophy (Evans index >0.3 on axial imaging). The large-volume CSF tap test — removal of 30–50 mL with assessment of gait before and 1–4 hours after — serves as a confirmatory functional test. Ventriculoperitoneal shunting can produce dramatic and sustained clinical improvement, particularly in gait and urinary symptoms, when performed before irreversible white matter injury occurs. This underscores the importance of early identification.

6. Atypical Parkinsonisms (Parkinson-Plus Syndromes)

The atypical parkinsonian syndromes — multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS) — each involve alpha-synuclein or tau proteinopathy extending beyond the nigrostriatal pathway to affect multiple neural systems, generating clinical features that transcend classical parkinsonism.

Multiple System Atrophy (MSA)

MSA is defined by parkinsonism combined with prominent autonomic failure (orthostatic hypotension, urogenital dysfunction), cerebellar ataxia, or both. The key differentiating feature is the severity and early timing of autonomic involvement: symptomatic orthostatic hypotension developing within the first year of motor symptom onset is a strong red flag against idiopathic PD. Characteristic MRI findings include the "hot cross bun sign" in the pons and putaminal atrophy with hypointense rim.

Progressive Supranuclear Palsy (PSP)

PSP is distinguished by vertical supranuclear gaze palsy — with downward saccades particularly impaired — early postural instability manifesting as backward falls, axial rigidity greater than appendicular, and frontal-predominant cognitive dysfunction. The "hummingbird sign" on midsagittal MRI (midbrain atrophy with preserved pontine volume, resembling a hummingbird in profile) supports the diagnosis. Levodopa response is typically absent.

Corticobasal Syndrome (CBS)

CBS presents with markedly asymmetric parkinsonism, limb apraxia, cortical sensory loss, and the pathognomonic alien limb phenomenon — involuntary, seemingly purposeful movements of one limb that the patient experiences as foreign to their volition. The histopathological substrate of CBS is heterogeneous and may include corticobasal degeneration (CBD), PSP, or Alzheimer's disease pathology. Levodopa response is typically absent.

7. Comparative Overview